Total trials
1,124
Active
236
Phase 3
47
Total enrollment
1,773,795
Pipeline matrix
Showing 40 of 88 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Aspirin | — | — | — | 6 | |||
| Warfarin | — | — | — | — | 4 | ||
| Prednisone | — | — | — | 3 | |||
| Clonidine | — | — | — | — | — | 2 | |
| growth hormone and lirglutide | — | — | — | — | — | 1 | |
| liraglutide | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| Gadopiclenol | — | — | — | — | — | 1 | |
| Suvorexant | — | — | — | — | — | 1 | |
| Naltrexone-Bupropion Combination | — | — | — | — | — | 1 | |
| Dexmedetomidine | — | — | — | — | — | 1 | |
| Growth Hormone | — | — | — | 4 | |||
| Tranexamic Acid | — | — | — | — | 2 | ||
| Apixaban | — | — | — | — | — | 2 | |
| Ketamine hydrochloride | — | — | — | — | — | 1 | |
| Morphine sulphate | — | — | — | — | — | 1 | |
| Prasugrel 5mg | — | — | — | — | — | 1 | |
| extended release metformin | — | — | — | — | — | 1 | |
| 18F- DCFPyL PET/CT | — | — | — | — | — | 1 | |
| Dietary supplements - Nicotinamide and Pyruvate | — | — | — | — | — | 1 | |
| Letermovir | — | — | — | — | — | 1 | |
| Valganciclovir | — | — | — | — | — | 1 | |
| Ferric carboxymaltose IV | — | — | — | — | — | 1 | |
| Normal Saline | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | 6 | ||
| 11C-ER176 | — | — | — | — | — | 3 | |
| Cemiplimab | — | — | — | — | — | 2 | |
| 18F-florbetaben | — | — | — | — | — | 2 | |
| 18F-MK6240 | — | — | — | — | — | 2 | |
| Gemcitabine | — | — | — | — | — | 4 | |
| Bendamustine | — | — | — | — | — | 3 | |
| Tocilizumab | — | — | — | — | 2 | ||
| Rituximab | — | — | — | — | — | 1 | |
| Romosozumab Prefilled Syringe [Evenity] | — | — | — | — | — | 1 | |
| Denosumab 60 MG/ML Prefilled Syringe [Prolia] | — | — | — | — | — | 1 | |
| Fianlimab | — | — | — | — | — | 1 | |
| UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis | — | — | — | — | — | 1 | |
| Sodium thiosulfate | — | — | — | — | — | 1 | |
| Venetoclax Oral Tablet, 200 mg | — | — | — | — | — | 1 | |
| Venetoclax Oral Tablet, 400 mg | — | — | — | — | — | 1 |
48 more active programs hidden
Next readouts
- 2022-12
- 2022-12
- 2025-05
- 2025-05-14
- 2025-10-21
- 2025-12-01
- 2026-04
- 2026-04-23
- 2026-06
- 2026-06
Top conditions
- Obesity28
- Stroke27
- HIV27
- Breast Cancer24
- HIV/AIDS19
- HIV Infections16
- Asthma15
- Heart Failure15
Frequently asked questions about Columbia University
- How many clinical trials does Columbia University have on ClinicalTrials.gov?
- Columbia University is listed as the lead sponsor on 1,124 clinical trials in ClinicalTrials.gov, 236 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Columbia University's trials are in Phase 3?
- 47 of Columbia University's trials are in Phase 3, spread across 88 active drug programs.
- What therapeutic areas does Columbia University focus on?
- Columbia University's most-studied conditions on ClinicalTrials.gov are Obesity, Stroke, HIV, Breast Cancer, HIV/AIDS.
- When are Columbia University's next clinical trial readouts?
- Columbia University has 10 upcoming primary-completion readouts tracked here; the soonest is “Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers”, expected around 2022-12.